An uncommon case of chronic myeloid leukemia with variant cytogenetic.

Abdullah, Mohamed A; Amer, Aliaa; Nawaz, Zafar; Abdullah, Ali S; Al-Sabbagh, Ahmad; Kohla, Samah; Nashwan, Abdulqadir J; Yassin, Mohamed A

Abdullah, Mohamed A; Amer, Aliaa; Nawaz, Zafar; Abdullah, Ali S; Al-Sabbagh, Ahmad; Kohla, Samah; Nashwan, Abdulqadir J; Yassin, Mohamed A.

Afiliação

Abdullah MA; Department of Medical Oncology, Hematology Section, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar. yassinmoha@gmail.com.
Amer A; Department of Laboratory Medicine and Pathology, Hamad Medical Corporation, Doha, Qatar. yassinmoha@gmail.com.
Nawaz Z; Department of Laboratory Medicine and Pathology, Hamad Medical Corporation, Doha, Qatar. yassinmoha@gmail.com.
Abdullah AS; Department of Medical Education, Internal Medicine Section, Hamad Medical Corporation, Doha, Qatar. yassinmoha@gmail.com.
Al-Sabbagh A; Department of Laboratory Medicine and Pathology, Hamad Medical Corporation, Doha, Qatar;. yassinmoha@gmail.com.
Kohla S; Clinical Pathology Department, Faculty of Medicine, AlAzhar University, Cairo, Egypt. yassinmoha@gmail.com.
Nashwan AJ; Department of Medical Oncology, Hematology Section, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar. yassinmoha@gmail.com.
Yassin MA; Department of Medical Oncology, Hematology Section, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar. yassinmoha@gmail.com.

Acta Biomed ; 89(3-S): 28-32, 2018 04 03.

Article em En | MEDLINE | ID: mdl-29633730

ABSTRACT

ABSTRACT

Chronic Myeloid Leukemia (CML) is myeloproliferative neoplasm characterized by Philadelphia chromosome which is a balanced translocation between chromosome 9 and 22 in 90% of cases. However, variant cytogenetic still happens in 5-10 % of cases, the importance of which is controversial as well as its response to therapy, prognosis and progression to acute leukemias. Here we report a male patient with CML and variant cytogenetic who responded to low dose of Dasatinib (50 mg daily).

Assuntos

Cariótipo Anormal; Leucemia Mielogênica Crônica BCR-ABL Positiva/genética; Translocação Genética; Antineoplásicos/uso terapêutico; Medula Óssea/patologia; Aberrações Cromossômicas; Cromossomos Humanos Par 17/genética; Cromossomos Humanos Par 17/ultraestrutura; Cromossomos Humanos Par 22/genética; Cromossomos Humanos Par 22/ultraestrutura; Cromossomos Humanos Par 9/genética; Cromossomos Humanos Par 9/ultraestrutura; Dasatinibe/uso terapêutico; Humanos; Hibridização in Situ Fluorescente; Leucemia Mielogênica Crônica BCR-ABL Positiva/tratamento farmacológico; Leucemia Mielogênica Crônica BCR-ABL Positiva/patologia; Masculino; Pessoa de Meia-Idade; Terapia de Alvo Molecular; Inibidores de Proteínas Quinases/uso terapêutico

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Translocação Genética / Leucemia Mielogênica Crônica BCR-ABL Positiva / Cariótipo Anormal Tipo de estudo: Prognostic_studies Limite: Humans / Male / Middle aged Idioma: En Revista: Acta Biomed Assunto da revista: MEDICINA Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Qatar

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google